Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The Journal of Clinical Investigation|May 20, 2005
Bacterial programmed cell death of cerebral endothelial cells involves dual death pathwaysDaniela Bermpohl, Annett Halle, Dorette Freyer, et al.Infection and Immunity|June 15, 2007
Pneumolysin causes neuronal cell death through mitochondrial damageJohann S Braun, Olaf Hoffmann, Miriam Schickhaus, et al.Journal of Neuroimmunology|September 15, 2007
Toll-like receptor 2 mediates CNS injury in focal cerebral ischemiaSeija Lehnardt, Sabrina Lehmann, David Kaul, et al.Immunity|August 23, 2003
Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding proteinJoerg R Weber, Dorette Freyer, Christian Alexander, et al.The Journal of Infectious Diseases|December 28, 2010
Bacterial pore-forming cytolysins induce neuronal damage in a rat model of neonatal meningitisAnja Reiss, Johann S Braun, Katja Jäger, et al.The Journal of Biological Chemistry|February 21, 2003
Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involvedNicolas W J Schröder, Siegfried Morath, Christian Alexander, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2006
A mechanism for neurodegeneration induced by group B streptococci through activation of the TLR2/MyD88 pathway in microgliaSeija Lehnardt, Philipp Henneke, Egil Lien, et al.The Journal of Clinical Investigation|June 16, 2007
TRAIL limits excessive host immune responses in bacterial meningitisOlaf Hoffmann, Josef Priller, Timour Prozorovski, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 24, 2006
Platelet-activating factor receptor and innate immunity: uptake of gram-positive bacterial cell wall into host cells and cell-specific pathophysiologySophie Fillon, Konstantinos Soulis, Surender Rajasekaran, et al.The Lancet. Neurology|December 15, 2023
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trialMukul Sharma, Carlos A Molina, Kazunori Toyoda, et al.Pageof 3